%0 Journal Article %A Daniele Barbaro %A Paola Lapi %A Paolo Viacava %A Liborio Torregrossa %T Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe %D 2020 %R 10.1136/bcr-2020-236934 %J BMJ Case Reports %P e236934 %V 13 %N 12 %X We report two cases of anaplastic thyroid cancer (ATC) which had a very good response to a treatment with lenvatinib at 14 mg. A 73-year-old man with ATC stage IVB was operated on, undergoing a near-total thyroidectomy, and the pathological remnant tissue showed a quick and partial response to treatment with the drug. The patient had a single metastasis in the brain after 9 months, but then died due to bronchopneumonia after undergoing a neurosurgical intervention for the complete removal of the lesion. A 74-year-old woman with ATC stage IV was operated on, undergoing a near-total thyroidectomy after a neoadjuvant treatment with the drug, that was continued after surgical treatment. She had a partial remission of the local disease and of distant metastasis, which lasted for 14 months. She then died 4 months later due to cancer progression. Lenvatinib at 14 mg appears to be effective, fast and well tolerated. %U https://casereports.bmj.com/content/bmjcr/13/12/e236934.full.pdf